Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This crossover trial is performed in advanced and metastatic pancreatic cancer not previously
exposed to chemotherapy. The study compares a standard arm with gemcitabine plus erlotinib to
an experimental arm with capecitabine plus erlotinib. It is the first trial of its kind to
incorporate second-line treatment into the study design. Patient who fail on first-line
therapy are switched to the comparator chemotherapy without erlotinib. The trial therefore
not only compares two different regimens of first-line treatment, it also compares two
sequential treatment strategies.